Description
Generic Drug of Bortezomib Available in India?
Bortezomib is the generic name of the medication and is its international nonproprietary name. Bortezomib is marketed under the brand name Borviz among others. Bortezomib Injection, a proteasome inhibitor, contains bortezomib, which is an antineoplastic agent. This NDA provides for the use of Bortezomib Injection for the treatment of adult patients with multiple myeloma and adult patients with mantle cell lymphoma.
Bortezomib, a first in class protease inhibitor (PI) was approved in 2003 for the treatment of progressive MM in patients who had received at least two prior therapies. In combination with melphalan and prednisone, it is also indicated for the treatment of adult patients with previously untreated MM who are not eligible for high-dose chemotherapy with hematopoietic stem cell transplantation. Currently, it has been recommended for primary induction therapy and also for consolidation and salvage therapy post relapse.
Since its development, bortezomib has come a long way in treating MM patients. Its wider therapeutic spectrum ranging from frontline induction to maintenance therapy has been increasingly explored in studies with the goal of achieving deeper responses, longer progression free survival (PFS), and possibly overall survival (OS). Bortezomib, in combination with other drugs, can also be reused in relapse setting.
Novel drugs, such as carfilzomib, Ixazomib, and pomalidomide, have also been introduced lately, leading to the bright future of MM patients.
Bortezomib was approved for medical use in the United States in 2003 and in the European Union in 2004. It is on the World Health Organization’s List of Essential Medicines. It is available as a generic medication.
Who is the CFA, distributor, and retailer for Borviz (Bortezomib) Injection in India?
Aark Pharmaceuticals is an authorized distributor, CFA (Carry and Forward Agent), and retailer for Borviz (Bortezomib) Injection in India. It is marketed by Intas. Aark claims to provide 100% authentic, cold-chain managed medicines. Aark supplies a wide range of Intas products, including advanced cancer treatments.
The company serves hospitals, clinics, and patients across India, including major cities like Bangalore, Surat, Kolkata, Indore, Nagpur, Patiala, Srinagar, Ahmedabad, Osmanabad, Mumbai, Pune, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Coimbatore, Kochi, Kollam, Agartala, Lucknow, Dehradun, Gairsain, Aizawal, Aurangabad, Barshi, Karungapally, Pondichery, Punjab, Delhi, New Delhi, Agra, Kanpur, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad, Wardha, Bhopal, Manipur, Mizoram, Sikkim, Tripura, Arunachal, Meghalaya, Nagaland, Pasighat, Cachar, Dibrugarh, Kamrup.
How much do Borviz Injection cost in Delhi, India?
Prices may vary based on your prescribed treatment plan. For accurate and the most cost-effective pricing on your prescription-recommended product, please contact Aark Pharmaceuticals
Contact Person: Ms. Himanshi
Address: S-14, Ground & Ist Floor, Green Park Extn., New Delhi-110016.
Do you offer any discounts?
Yes. Based on availability, prices may vary based on your prescribed treatment plan. Please ask for the best current price.
Prior to consuming any medications, including Bortezomib Injection, it is advisable to seek guidance from a medical professional regarding its therapeutic advantages, usage instructions, and potential side effects.
List of available brand-name drugs in India for Bortezomib Injection.
Indian pharmaceutical company has received approval from the US Food and Drug Administration (USFDA) for its product, ‘Bortezomib Injection NDA 212782’.
List of Generic version of Bortezomib for injection available with Aark: Bortether, Proteoz, Myzomib, Myezom, Mibor, Borviz, Bortrac, Bortirel, Borteshil, Borteplus, Bortenat , Bortemap, Borte Trust.
NEWS / UPDATES
- Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and Ukraine.
- GSK blood cancer drug nearly halves risk of death in late-stage trial.
- Dr. Reddy’s Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market.
- Aurobindo Pharma gets USFDA nod for generic cancer drug Bortezomib.
- Zydus receives final approval from USFDA for Bortezomib for Injection.
Written By
Mr. Sandeep Tomar (D. pharma)
Last updated
04 January 2026 | 10:10 AM (IST)
